Page last updated: 2024-12-06

copper

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cuprous ion: RN given refers to Cu(1+) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	104815
CHEBI ID	49552
MeSH ID	M0005152

Synonyms (38)

Synonym
139076-62-3
kogenate fs
copper(i) ion
copper(1+)ions
copper, ion (cu1+) (8ci,9ci)
cu(i)
copper(1+)
copper ion (cu+)
cu1+
cuprous ion (cu1+)
copper ion(1+)
17493-86-6
cuprous cation
cuprous copper
copper(i)
cuprous ion
octocog alfa
CHEBI:49552
cu(+)
bay-w 6240
obizur
helixate nexgen
helixate fs
octocog alfa [inn:ban]
bay w 6240
p89dr4ny54 ,
helixate
bay-14-2222
kogenate
blood-coagulation factor viii (human), glycoform alpha
unii-p89dr4ny54
copper, ion (cu1+)
copper (i)
VMQMZMRVKUZKQL-UHFFFAOYSA-N
copper (+1)
copper (1)
DTXSID30169912
Q27104705

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

Role	Description
cofactor	An organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

Class	Description
copper cation
monoatomic monocation
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (28)

Pathway	Proteins	Compounds
Transport of small molecules	392	95
Ion channel transport	45	16
Ion transport by P-type ATPases	13	12
Cellular responses to stimuli	483	56
Response to metal ions	14	5
Metallothioneins bind metals	11	5
Cellular responses to stress	469	54
Detoxification of Reactive Oxygen Species	30	27
Immune System	914	82
Innate Immune System	414	75
Antimicrobial peptides	38	18
Ion influx/efflux at host-pathogen interface	4	6
Cellular response to chemical stress	167	40
Copper metabolism	0	2
nitrate reduction VIIIb (dissimilatory)	4	11
colanic acid building blocks biosynthesis	9	49
NADH to cytochrome bd oxidase electron transfer II	4	18
NADH to cytochrome bo oxidase electron transfer II	5	26
coenzyme M biosynthesis I	5	28
glycogen degradation I	8	50
D-galactose degradation I (Leloir pathway)	10	46
methane oxidation to methanol II	3	5
glycogen biosynthesis I (from ADP-D-Glucose)	4	25
UDP-u03B1-D-glucose biosynthesis I	14	24
superpathway of UDP-glucose-derived O-antigen building blocks biosynthesis	11	39
glucose and glucose-1-phosphate degradation	4	34
Sulfate assimilation and copper detoxification	0	20
Copper homeostasis	0	2

Research

Studies (44)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (11.36)	18.7374
1990's	5 (11.36)	18.2507
2000's	19 (43.18)	29.6817
2010's	12 (27.27)	24.3611
2020's	3 (6.82)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	44 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (116)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Targeting a Genomic Biomarker for PET Imaging and Staging of Urothelial Cancer: A Preliminary Evaluation [NCT03039413]	Early Phase 1	20 participants (Actual)	Interventional	2016-09-28	Active, not recruiting
Copper Antimicrobial Research Program: Environmental and Patient Sampling For Indicator Organisms To Determine The Efficacy Of Copper To Reduce Acquisition Of Microbes From The Patient Care Environment [NCT01565798]		614 participants (Actual)	Interventional	2010-07-31	Completed
Intrauterine Contraception for Adolescents Aged 14 to 18: A Multi-center Randomized Controlled Feasibility Trial of Levonorgestrel-releasing Intrauterine System Compared to the Copper T 380A [NCT00653159]	Phase 4	23 participants (Actual)	Interventional	2007-07-31	Completed
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Patients With Treatment-Refractory Sarcomas [NCT05210374]	Phase 1	24 participants (Anticipated)	Interventional	2023-03-09	Recruiting
An Innovative Approach to Understanding and Controlling Transmission of HAIs [NCT02627092]		424 participants (Anticipated)	Interventional	2016-01-31	Active, not recruiting
A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate When Added to Standard Temozolomide Treatment in Patients With Newly Diagnosed Resected Unmethylated Glioblastoma Multiforme [NCT03363659]	Phase 2	15 participants (Actual)	Interventional	2018-03-28	Terminated(stopped due to Investigator decision)
A Post-Marketing, Prospective, Multi-Center, Single Arm, Open Label Clinical Study to Evaluate the Safety of a New Inserter Design for Paragard® T380A Intrauterine Copper Contraceptive [NCT05309694]	Phase 4	119 participants (Actual)	Interventional	2022-03-04	Completed
Patient Compliance With Long-Acting Reversible Contraception Administration Immediately and Early Postpartum Versus Interval Postpartum [NCT03305081]		45 participants (Actual)	Interventional	2014-10-22	Terminated
Phase 1 Open Label Study of Zinc Therapy in ALS Patients [NCT01259050]	Phase 1/Phase 2	10 participants (Anticipated)	Interventional	2010-10-31	Completed
Comparative Study of Intrauterine Contraceptive Device Insertion During Caesarean Section Versus Conventional Application [NCT02674139]	Phase 4	8 participants (Anticipated)	Interventional	2016-02-29	Enrolling by invitation
Imaging of Solid Tumors Using FAP-2286 [NCT04621435]	Phase 1	116 participants (Anticipated)	Interventional	2020-12-14	Recruiting
Short Course Radiotherapy Based Total Neoadjuvant Therapy With or Without Chlorophyllin (SCOTCH Study) [NCT05856305]	Phase 2	76 participants (Anticipated)	Interventional	2023-07-05	Recruiting
Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver [NCT00742911]	Phase 1	21 participants (Actual)	Interventional	2008-07-31	Completed
Early Copper Histidine Therapy in Menkes Disease [NCT00001262]	Phase 1/Phase 2	60 participants (Actual)	Interventional	1990-06-30	Completed
Immediate Versus Delayed Insertion of the Copper IUD After Second-trimester Medical Abortion - a Randomised Controlled Trial. [NCT03505047]		110 participants (Actual)	Interventional	2018-05-10	Completed
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency [NCT00811785]	Phase 3	93 participants (Actual)	Interventional	2009-02-27	Completed
A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine [NCT02226276]		10 participants (Actual)	Interventional	2015-01-07	Active, not recruiting
The Effect of 30mcg and Levonorgestrel 150 Combined Oral Contraceptive, Etonogestrel-releasing Subdermal Implant and Levonorgestrel-releasing Intrauterine System on Breast-Milk Production and Infant Growth in Fully Breast-Feeding Women [NCT01388582]	Phase 4	40 participants (Actual)	Interventional	2011-04-30	Completed
Immediate vs. Delayed Post-abortal Copper T 380A IUD Insertion in Cases Over 12 Weeks of Gestation [NCT00540046]		215 participants (Actual)	Interventional	2007-04-30	Completed
Comparison of Wound Healing Efficacy Between MedCu Wound Dressings With Copper Oxide and Negative Pressure Wound Therapy (NPWT/VAC) Treatment [NCT05215730]		46 participants (Actual)	Interventional	2021-07-07	Completed
Preventing Future Pregnancy After Choosing the Copper IUD vs. Oral Levonorgestrel for Emergency Contraception [NCT00966771]		548 participants (Actual)	Observational	2009-10-31	Completed
A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome [NCT01291628]		10 participants (Anticipated)	Interventional	2012-01-31	Not yet recruiting
A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma [NCT03034135]	Phase 2	23 participants (Actual)	Interventional	2017-03-09	Completed
An Open-Label, Randomized Study to Determine the Safety and Efficacy of LUXSOL(TM) Cream for the Treatment of Bacterial Vaginosis: A Proof of Concept Study [NCT02197182]	Early Phase 1	50 participants (Actual)	Interventional	2014-06-30	Terminated(stopped due to Not for safety reasons)
A Randomized Trial of Immediate Versus Delayed Insertion of the Copper T380A Following Medication Abortion [NCT00737178]	Phase 4	156 participants (Actual)	Interventional	2008-07-31	Completed
Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial [NCT03936426]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2018-07-09	Completed
A Combination of Zinc, Chromium, Vitamin C, and Copper Supplement for Prediabetes Progression: Randomized Controlled-Trial in Jakarta [NCT04511468]		670 participants (Anticipated)	Interventional	2021-06-23	Recruiting
Pilot Efficacy Study of MedCu Wound Dressings With Copper Oxide in Treating Pressure Sores and Post-op Wounds [NCT04634838]		20 participants (Actual)	Interventional	2021-02-02	Terminated(stopped due to In view of the very positive results obtained with the copper dressings after 20 patients, the researchers decided to apply copper dressings from the beginning of wound management, not to use anymore silver dressings and to terminate the trial.)
This Study is a Small Preliminary Study to Evaluate the Possibility of Performing a Phase 1 Study. [NCT00846144]		100 participants (Anticipated)	Interventional	2009-09-30	Not yet recruiting
[NCT02679820]		500 participants (Actual)	Interventional	2016-01-31	Completed
A Pilot Study Of A Randomized Trial Comparing Two Different Time Frames For Copper T380A Intrauterine Contraception Insertion; Immediately Postpartum Compared To 4-6 Weeks Postpartum In Lilongwe, Malawi [NCT01175161]		115 participants (Actual)	Interventional	2010-10-31	Completed
Human Biomarkers for Assessing Copper Deficiency and Repletion: A Pilot Study [NCT01177579]	Phase 1	70 participants (Anticipated)	Interventional	2010-11-30	Recruiting
The Safety and Efficacy of Immediate Post Placental IUD Insertion Versus the Post Puerperal IUD Insertion in Patients Undergoing Cesarean Delivery [NCT04630548]		66 participants (Anticipated)	Interventional	2020-12-01	Not yet recruiting
Prospective Assessment of Acceptability and Adherence Associated With Use of the Copper Intrauterine Device (CuT380A-IUCD) Compared to Depo-medroxyprogesterone Acetate (DMPA) Among HIV Positive Women in Lilongwe, Malawi [NCT01191203]		200 participants (Actual)	Interventional	2010-07-31	Completed
An Open-Label, Multi-Center Expanded Access Protocol of Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of Somatostatin Receptor Expressing Neuroendocrine Tumors (NETs) [NCT04334837]		0 participants	Expanded Access		Approved for marketing
Assessment of the Diagnostic Value of 64Cu-SAR-BBN PET Imaging for Men With Negative PSMA PET in Prostate Cancer [NCT05613842]	Phase 2	30 participants (Actual)	Interventional	2022-08-09	Completed
Immediate Post Placental Insertion of Intrauterine Device at Cesarean Delivery, is Acceptable, Feasible and Safe in Iraqi Women. [NCT04136613]		150 participants (Actual)	Interventional	2015-09-01	Completed
Mucosal and Systemic Responses to Contraceptives in HIV-Infected Women in Zambia [NCT00807625]	Phase 2	66 participants (Actual)	Interventional	2008-11-30	Completed
A Multi Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women Using Depot Medroxyprogesterone Acetate (DMPA), Levonorgestrel (LNG) Implant, and Copper Intrauterine Devices (IUDs) [NCT02550067]		7,830 participants (Actual)	Interventional	2015-12-14	Completed
64Cu-DOTA-trastuzumab Positron Emission Tomography in Patients With Gastric Cancer [NCT01939275]		8 participants (Actual)	Interventional	2014-11-19	Active, not recruiting
Imaging the HIV Reservoir [NCT03063788]	Phase 1	17 participants (Actual)	Interventional	2018-09-18	Completed
Efficiency of Using Copper-Nickel-Titanium Versus Nickel-Titanium Arch Wires on Anterior Segment Crowding Alleviation in Group of Adults With Moderate Crowding: A Randomized Controlled Clinical Trial [NCT04815200]		30 participants (Anticipated)	Interventional	2021-03-18	Recruiting
A Randomized, Single-blind, Trial of Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Manganese Safety in Pediatric Patients Requiring Long-term Parenteral Nutrition [NCT05677126]	Phase 4	80 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
A Randomized, Single-blind, Trial of Tralement Versus a Fixed-dose Trace Element Combination Product of Zinc, Copper, and Selenious Acid to Evaluate Manganese Safety in Adult Patients Requiring Long-term Parenteral Nutrition [NCT05661682]	Phase 4	108 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
A Phase II Pilot Study of Disulfiram and Copper Gluconate in Patients With Metastatic Pancreatic Cancer and Rising CA-19-9 Levels While Receiving Abraxane-Gemcitabine or FOLFIRINOX or Single-Agent Gemcitabine [NCT03714555]	Phase 2	1 participants (Actual)	Interventional	2019-10-17	Terminated(stopped due to Study was closed due to low subject enrollment at site.)
A Pilot Phase I Open Label Study of Cu-64-TP3805 PET Imaging for Detection of Prostate Cancer in Men Undergoing Radical Prostatectomy [NCT02603965]	Phase 1	25 participants (Actual)	Interventional	2013-08-31	Completed
Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs [NCT00461253]		25,565 participants (Actual)	Observational	2006-10-31	Completed
A Non-interventional Study to Observe the Bleeding Pattern of LNG-IUS Inserted Immediately After Surgical Abortion Compared With Copper IUD [NCT01958684]		512 participants (Actual)	Observational	2013-10-31	Completed
Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzum-Based Neoadjuvant Therapy [NCT02827877]	Phase 2	18 participants (Actual)	Interventional	2016-07-15	Active, not recruiting
Effectiveness of Early Versus Standard Insertion of Post Abortion Intrauterine Contraception After First Trimester Medical Management of Incomplete Abortion in Central Uganda: A Non-Inferiority Randomized Clinical Trial [NCT05343546]		2,076 participants (Anticipated)	Interventional	2022-06-30	Not yet recruiting
A First-in-Human, Phase I/II PET Imaging Study of 64Cu-GRIP B, a Radiotracer Targeting Granzyme B, in Patients With Advanced Malignancies [NCT05888532]	Phase 1/Phase 2	91 participants (Anticipated)	Interventional	2023-05-25	Recruiting
Study of the VeraCept Intrauterine Device for Long Acting Reversible Contraception [NCT02167763]	Phase 1	300 participants (Anticipated)	Interventional	2013-11-30	Completed
DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial [NCT02678975]	Phase 2/Phase 3	88 participants (Actual)	Interventional	2017-01-31	Completed
Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality [NCT01805817]	Phase 4	0 participants (Actual)	Interventional	2012-12-31	Withdrawn
Impact of Intrauterine Contraception on the Immune Environment of the Female Genital Tract [NCT01240811]		42 participants (Actual)	Interventional	2010-11-30	Completed
Insertion of an IUD After Medical Abortion [NCT00621543]		120 participants (Actual)	Interventional	2006-03-31	Completed
[NCT00608946]	Phase 2	68 participants (Actual)	Interventional	2004-03-31	Completed
A Pilot Study of Copper T380A IUDs Versus Oral Levonorgestrel for Emergency Contraception [NCT00669396]		57 participants (Actual)	Interventional	2008-04-30	Completed
Transcesarean IUD Insertion: A Prospective Cohort Study [NCT01439802]	Phase 4	90 participants (Actual)	Interventional	2008-08-31	Completed
New Method of IUD Insertion During Cesarian Section [NCT05756998]		156 participants (Anticipated)	Interventional	2022-02-02	Recruiting
64Cu-DOTA-B-Fab as A PET Tracer for Evaluating CA6 Expression in Tumors: A First in Human Study [NCT02708511]	Phase 1	2 participants (Actual)	Interventional	2016-08-31	Terminated
Acceptability and Technical Feasibility of Insertion of a Copper IUD at Time of Elective C-section: A Pilot Study [NCT00733278]	Phase 4	7 participants (Actual)	Interventional	2007-11-30	Completed
DIU-QoL. Quality of Life Evaluation in Intrauterine Device Users. [NCT01731132]		207 participants (Actual)	Observational	2012-07-31	Completed
Comparative of Two Devices (Conventional Intrauterine Devices (Cu T380 A)/Frameless Intrauterine Devices (GyneFix)) for Postpartum Immediate Contraception in Cesarean Deliveries [NCT02941198]		140 participants (Actual)	Interventional	2016-06-01	Completed
Postpartum Glucose Tolerance in Women With Recent Gestational Diabetes Using the Levonorgestrel IUD and Non-Hormonal Contraception: A Prospective Cohort Study [NCT01022645]		42 participants (Actual)	Observational	2009-11-30	Completed
A Pharmacodynamic Study of Proteasome Inhibition by Disulfiram in Patients With Glioblastoma [NCT01907165]	Early Phase 1	21 participants (Actual)	Interventional	2013-10-10	Completed
Phase II Study of Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer. [NCT04265274]	Phase 2	0 participants (Actual)	Interventional	2020-01-01	Withdrawn(stopped due to Poor acrual)
A Phase I Study of 64Cu Pembrolizumab PET Imaging for In Vivo Expression of PD1 [NCT04605614]	Phase 1	0 participants (Actual)	Interventional	2022-08-15	Withdrawn(stopped due to slow accruals)
Acceptability and Continuation Rate of Implanon in a Brazilian Public Sector [NCT01392157]	Phase 4	300 participants (Actual)	Interventional	2011-06-30	Completed
A Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease [NCT02870634]	Phase 1	50 participants (Anticipated)	Interventional	2016-11-16	Completed
The Effect of a Levonorgestrel-releasing Intrauterine Device Versus a Copper Containing Intrauterine Device on Coagulation Parameters [NCT00584610]		50 participants (Anticipated)	Interventional	2007-12-31	Recruiting
A Prospective Trial of the Copper T380 IUD or Oral Levonorgestrel and the Levonorgestrel IUD Initiated With Emergency Contraception [NCT01963962]		188 participants (Actual)	Observational	2013-07-31	Completed
PET Imaging of Breast Cancer Using Oncogene Expression [NCT02810873]		19 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to Study terminated by PI)
Zinc and Biobehavioral Development in Early Childhood [NCT00589264]		251 participants (Actual)	Interventional	2004-07-31	Completed
64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women With Advanced HER2 Positive Invasive Breast Cancer [NCT01093612]		18 participants (Actual)	Interventional	2011-03-16	Active, not recruiting
A Randomized Trial of IUD Versus Hormonal Contraception in HIV-infected Women in Zambia [NCT00336245]	Phase 3	600 participants	Interventional	2002-06-30	Completed
A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Complete Study CMD-2019-001 [NCT04313166]	Phase 2	55 participants (Actual)	Interventional	2020-03-19	Completed
Prospective Multicentre Non-interventional Comparative Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction [NCT01590537]		2,348 participants (Actual)	Observational	2011-09-30	Completed
Metallic Nanoparticles: Evaluation of Their Antibacterial, Antibiofilm and Synergistic Effect in Combination With Antibiotics on Nosocomial Bacteria [NCT04775238]		100 participants (Anticipated)	Interventional	2021-02-27	Recruiting
Use of 64Cu-DOTA-Alendronate PET Imaging for Localization and Characterization of Breast Calcifications [NCT03542695]	Early Phase 1	1 participants (Actual)	Interventional	2021-11-03	Active, not recruiting
Evaluation of Non-B Non-C Liver Cirrhosis in A EL-Rajhi Assuit University Hospital: A Retrospective-Prospective Study [NCT05314270]		100 participants (Anticipated)	Observational	2022-10-01	Not yet recruiting
Satisfaction, Continuity, and Bleeding Patterns in Patients With Breast Cancer Using Copper and Silver Intrauterine Device (IUD) Compared to Copper IUD: a Randomized Clinical Trial [NCT05148910]		90 participants (Anticipated)	Interventional	2020-08-06	Recruiting
A Phase I Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple Myeloma [NCT04521335]	Phase 1	2 participants (Actual)	Interventional	2021-05-21	Terminated(stopped due to Closed at PI's Request)
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer [NCT02963051]	Phase 1	9 participants (Actual)	Interventional	2017-07-11	Terminated(stopped due to Study stopped due to lack of efficacy.)
Pilot Study: Imaging Tumor Extent and Response Before and After Neoadjuvant Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA) [NCT05245786]	Early Phase 1	15 participants (Anticipated)	Interventional	2022-08-31	Recruiting
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors [NCT06016855]	Phase 4	6 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
Copper Histidinate Treatment for Menkes Disease [NCT04074512]		0 participants	Expanded Access		Available
Randomised Controlled Trial on the Effect of Copper Impregnated Dressings and Maternity Pads on the Healing of Obstetric Wounds and Wound Infection [NCT03284749]		774 participants (Actual)	Interventional	2016-01-14	Completed
RAPID EC - Randomized Controlled Trial Assessing Pregnancy With Intrauterine Devices for Emergency Contraception [NCT02175030]	Phase 4	711 participants (Actual)	Interventional	2016-08-31	Completed
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk Neuroblastoma: A Multi-center, Dose-escalation, Open-label, Non-randomized, Phase 1-2a Theranostic Clinical Trial [NCT04023331]	Phase 1/Phase 2	34 participants (Anticipated)	Interventional	2020-08-18	Recruiting
A PHASE II CLINICAL TRIAL FOR THE EVALUATION OF THE EFFICACY OF DISULFIRAM/COPPER COMBINATION AS AN ADJUVANT AND CONCURRENT CHEMOTHERAPY IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORM [NCT01777919]	Phase 2	32 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
Safe Maternity Care Through Immediate Provision of Highly-effective Postpartum Contraception [NCT03389958]		299 participants (Actual)	Observational	2015-10-01	Completed
A Phase I/II Dose-escalation and Dose-expansion Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma [NCT02715609]	Phase 1/Phase 2	35 participants (Actual)	Interventional	2016-06-15	Active, not recruiting
Pilot Trial Using 64Cu-DOTA Pembrolizumab (64CDP) in Patients Receiving Stereotactic Body Radiation Therapy for Oligo-Progressive Solid Tumors [NCT05728372]	Early Phase 1	0 participants (Actual)	Interventional	2023-08-25	Withdrawn(stopped due to withdrawn per PI)
A Phase II Study to Evaluate Oral Chlorophyllin in Hemorrhagic Cystitis Secondary to Radiation Therapy for Pelvic Malignancies [NCT05348239]	Phase 2	24 participants (Anticipated)	Interventional	2022-03-26	Recruiting
Effect of Copper Impregnated Textiles on Healthcare Associated Infections and Antibiotic Use in a Single Intensive Care Unit [NCT02351895]		1,302 participants (Actual)	Observational	2014-01-31	Completed
Safety and Efficacy Study of MedCu Wound Dressings With Copper Oxide [NCT04963998]		13 participants (Actual)	Interventional	2019-10-02	Completed
A Pilot Phase I Open Label Study of Cu-64-TP3805 PET Imaging for Detection of Prostate Cancer in Men With Persistently Elevated PSA [NCT02989623]		20 participants (Actual)	Interventional	2015-09-01	Completed
Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease [NCT04965545]		1,000 participants (Anticipated)	Observational	2004-01-01	Recruiting
Copper Use as Protection Against Antimicrobial Resistance in the ICU [NCT04873557]		168 participants (Actual)	Interventional	2020-11-02	Completed
(TRIBE) Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users [NCT02311478]		79 participants (Actual)	Interventional	2014-12-31	Completed
Clinical Profile and Out Come of Children With Wilson's Disease :A Single Tertiary Center Study . [NCT05792319]		20 participants (Anticipated)	Observational	2023-12-20	Not yet recruiting
Correlation Between Uterine Artery Doppler Indices and Menstrual Changes After Insertion of Copper Intrauterine Contraceptive Device and Levonorgestrel Intrauterine System [NCT05986344]		165 participants (Anticipated)	Observational	2023-08-30	Not yet recruiting
Rates of Contraceptive Failure When Unprotected Intercourse Has Occurred 6-14 Days Prior to Contraceptive Initiation [NCT02076217]		1,030 participants (Anticipated)	Observational	2014-02-28	Active, not recruiting
Micronutrient Status Involved in Immunity in Elderly Patients With COVID-19 [NCT04877509]		229 participants (Actual)	Observational	2020-03-01	Completed
A Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's Disease [NCT03204929]	Phase 1	31 participants (Actual)	Interventional	2017-08-14	Completed
ArchWire-RaCE: Orthodontic Archwires: a Randomised Clinical Trial of Effectiveness [NCT02659813]		64 participants (Actual)	Interventional	2016-10-31	Completed
Comparison of Two IUDs Among Cape Town HIV-positive Women: A Randomized Controlled Trial Assessing Safety of Registered Products in South Africa [NCT01721798]		205 participants (Actual)	Interventional	2013-11-10	Completed
Efficacy of Copper in Reducing Health-Acquired Infections and Microbial Burden as Measured on High Touch Surfaces in a Pediatric Intensive Care Unit. A Controlled Clinical Trial. [NCT01678612]		1,012 participants (Actual)	Interventional	2012-11-30	Completed
SmartWire Multiforce Archwire Clinical Trial [NCT02983084]		105 participants (Anticipated)	Interventional	2016-12-01	Active, not recruiting
Somatostatin Receptor Imaging Study of Estrogen Receptor Positive (ER+) Metastatic Breast Cancer [NCT05880394]	Phase 1	30 participants (Anticipated)	Interventional	2023-01-10	Active, not recruiting
Particle-based Partial Tumor Irradiation Targeting Hypoxic Segment and Sparing the Peritumoral Immune Microenvironment for Unresectable Bulky Tumors [NCT04875871]		22 participants (Anticipated)	Interventional	2021-11-11	Recruiting
Impact of Copper Compression Stockings on Venous Insufficiency and Lipodermatosclerosis: a Randomised Controlled Trial [NCT03283800]		16 participants (Actual)	Interventional	2015-09-23	Completed
Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk [NCT02357368]	Phase 4	59 participants (Actual)	Interventional	2015-02-28	Completed
The UMPALA Study: A Clinical Study to Assess the Impact of Contraceptives on the Cervico-Vaginal Mucosa [NCT04814927]	Phase 4	112 participants (Actual)	Interventional	2021-03-01	Completed
A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001 [NCT03136809]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2018-01-18	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00001262 (7) [back to overview]	Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Length Percentile
NCT00001262 (7) [back to overview]	Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Weight Percentile
NCT00001262 (7) [back to overview]	Fine Motor Adaptive Development at 36 Mos of Age or at Death (Mos)
NCT00001262 (7) [back to overview]	Gross Motor Development at 36 Mos of Age or at Death (Mos)
NCT00001262 (7) [back to overview]	Language Development at 36 Mos of Age or at Death (Mos)
NCT00001262 (7) [back to overview]	Personal-Social Development at 36 Mos of Age or at Death (Mos)
NCT00001262 (7) [back to overview]	Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Head Circumference Percentile
NCT00461253 (1) [back to overview]	Breast Cancer Risk
NCT00540046 (2) [back to overview]	Use of IUD
NCT00540046 (2) [back to overview]	Expulsion
NCT00621543 (2) [back to overview]	Percentage of Women Continuing IUD Use at 3 Months
NCT00621543 (2) [back to overview]	Percentage of Women With Expulsion of an Intrauterine Device (IUD) Placed After Medical Abortion.
NCT00653159 (5) [back to overview]	Expulsion Rates
NCT00653159 (5) [back to overview]	Heavy Bleeding Rates
NCT00653159 (5) [back to overview]	Pregnancy Rates
NCT00653159 (5) [back to overview]	Retention Rate
NCT00653159 (5) [back to overview]	Device Satisfaction Rates
NCT00669396 (4) [back to overview]	Infection
NCT00669396 (4) [back to overview]	Use of an Effective Method of Contraception at 6 Months After Requesting Emergency Contraception
NCT00669396 (4) [back to overview]	Pregnancy
NCT00669396 (4) [back to overview]	IUD Expulsion, Removal, or Perforation
NCT00733278 (2) [back to overview]	Successful Retention of IUD
NCT00733278 (2) [back to overview]	Visibility Within the Vagina of IUD Strings at All Times.
NCT00737178 (3) [back to overview]	Insertion Rates
NCT00737178 (3) [back to overview]	Use of the IUD for Contraception at Six Months
NCT00737178 (3) [back to overview]	Expulsion and Removal Rates
NCT01093612 (2) [back to overview]	Tumor Uptake of 64Cu-DOTA-trastuzumab After 24 Hours
NCT01093612 (2) [back to overview]	Tumor Uptake of 64Cu-DOTA-trastuzumab After 48 Hours
NCT01240811 (3) [back to overview]	Change in Quantities of Vaginal H2O2-producing Lactobacillus Species and Gardnerella Vaginalis
NCT01240811 (3) [back to overview]	Change in Vaginal Flora
NCT01240811 (3) [back to overview]	%CD4 Expressing CCR5 HIV Co-receptor in the Cervix and Endometrium
NCT01439802 (3) [back to overview]	Number of Participants With Expulsion of IUD
NCT01439802 (3) [back to overview]	Number of Participants With Expulsion of IUD
NCT01439802 (3) [back to overview]	Satisfaction of IUD Placement
NCT01939275 (1) [back to overview]	Number of HER2 Negative, Positive, or Equivocal Participants With Either Negative or Positive Tumor Readings
NCT02175030 (2) [back to overview]	Number of Participants With Unintended Pregnancy After Initiating the Levonorgestrel IUD Versus the Copper T380 IUD for EC at One Year.
NCT02175030 (2) [back to overview]	Percentage of Participants Reporting a Pregnancy
NCT02226276 (2) [back to overview]	Relationship Between Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response
NCT02226276 (2) [back to overview]	Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response
NCT02311478 (3) [back to overview]	Assess the Relationship of Menstrual Cycle Changes Among Women Initiating the Copper T380 IUD to Sexual Functioning and Satisfaction
NCT02311478 (3) [back to overview]	Assess the Relationship of Menstrual Cycle Changes Among Women Initiating the Copper T380 IUD to Method Satisfaction and Continuation at 6 Months Post Insertion.
NCT02311478 (3) [back to overview]	Evaluate Changes in Bleeding Duration Among Women Initiating the Copper T380 IUD During the 90 Days Prior to Initiation Compared to Two 90 Periods After IUD Insertion.
NCT02357368 (4) [back to overview]	Concentration Levels of Secreted Cytokines and Chemokines Within the Female Genital Mucosa and Blood
NCT02357368 (4) [back to overview]	Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood
NCT02357368 (4) [back to overview]	Percent of Markers of T-cell Activation and Trafficking Within the Female Genital Mucosa and Blood
NCT02357368 (4) [back to overview]	Ratio of CD4/Cluster of Differentiation 8 (CD8) T-Cells Within Female Genital Mucosa and Blood
NCT02810873 (1) [back to overview]	Number of F-18-FDG Positive Lesions That Are Detected by the Copper Cu 64 TP3805 Analog
NCT02827877 (1) [back to overview]	SUV Measurement by 64Cu-DOTA Trastuzumab PET
NCT03034135 (6) [back to overview]	Median Duration of Overall Survival
NCT03034135 (6) [back to overview]	Number of Participants With Serious Adverse Events
NCT03034135 (6) [back to overview]	Overall Survival
NCT03034135 (6) [back to overview]	Objective Response Rate
NCT03034135 (6) [back to overview]	Progression Free Survival
NCT03034135 (6) [back to overview]	Median Progression Free Survival
NCT03305081 (2) [back to overview]	Number of Women With Placement of LARC
NCT03305081 (2) [back to overview]	Patient Satisfaction With Method of LARC Using LARC Survey
NCT03363659 (2) [back to overview]	Overall Survival
NCT03363659 (2) [back to overview]	6 Months Progression Free Survival (PFS)

Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Length Percentile

(NCT00001262)
Timeframe: 36 months or death

Intervention	Other - Percentile (Mean)
Early	8.286
Late	15.455
Mild	28.333

[back to top]

Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Weight Percentile

(NCT00001262)
Timeframe: 36 months or death

Intervention	Other - Percentile (Mean)
Early	12.086
Late	11.273
Mild	5.000

[back to top]

Fine Motor Adaptive Development at 36 Mos of Age or at Death (Mos)

This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate fine motor development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age. (NCT00001262)
Timeframe: 36 months or death

Intervention	Other - Months (Mean)
Early	16.200
Late	2.409
Mild	17.667

[back to top]

Gross Motor Development at 36 Mos of Age or at Death (Mos)

This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate gross motor development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age. (NCT00001262)
Timeframe: 36 months or death

Intervention	Other - months (Mean)
Early	13.743
Late	2.455
Mild	15.667

[back to top]

Language Development at 36 Mos of Age or at Death (Mos)

This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate language development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age. (NCT00001262)
Timeframe: 36 months or death

Intervention	Other - Months (Mean)
Early	15.800
Late	3.227
Mild	21.000

[back to top]

Personal-Social Development at 36 Mos of Age or at Death (Mos)

This was measured based on the Denver Developmental Screening Test (DDST) I or II for age-appropriate personal-social development in apparently normal healthy subjects at specific ages (in months). The DDST employs a grid to assess expected developmental milestones in relation to chronologic age. (NCT00001262)
Timeframe: 36 months or death

Intervention	Other - Months (Mean)
Early	17.657
Late	3.364
Mild	17.667

[back to top]

Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Head Circumference Percentile

(NCT00001262)
Timeframe: 36 months or death

Intervention	Other - Percentile (Mean)
Early	33.286
Late	11.136
Mild	18.333

[back to top]

Breast Cancer Risk

Breast cancer (invasive carcinoma or carcinoma in situ) in women aged <50 years at diagnosis. Cases were excluded if they had died before study start or had a history of malignancy. (NCT00461253)
Timeframe: retrospective, January 2000 to December 2007

Intervention	participants (Number)
LNG IUD	1076
Cu-IUD	1068

[back to top]

Use of IUD

Number of participants using Copper T380A IUD 6 months after surgery (NCT00540046)
Timeframe: 6 months

Intervention	participants (Number)
A/Immediate	58
B/Delayed	25

[back to top]

Expulsion

IUD was not removed by provider but fell out on its own. (NCT00540046)
Timeframe: 6 months

Intervention	percentage of expulsions (Number)
A/Immediate	3.1
B/Delayed	0

[back to top]

Percentage of Women Continuing IUD Use at 3 Months

(NCT00621543)
Timeframe: 3 months

Intervention	percentage of participants (Mean)
Single Arm Study	80.

[back to top]

Percentage of Women With Expulsion of an Intrauterine Device (IUD) Placed After Medical Abortion.

(NCT00621543)
Timeframe: Three months

Intervention	percentage of participants (Mean)
Single Arm Study	4

[back to top]

Expulsion Rates

Rates of partial or complete expulsion for teens randomized to the LNG-IUS or Copper T 380A. Patients experiencing partial expulsion had IUDs visible on speculum exam. Complete expulsion is characterized by complete evacuation of the IUD. (NCT00653159)
Timeframe: 6 months

Intervention	percentage of randomized subjects (Number)
Paragard IUD [CuT380A]	18
Mirena IUD [LNG-IUS]	0

[back to top]

Heavy Bleeding Rates

Rates of participants experiencing heavy bleeding among teens randomized to the LNG-IUS or Copper T 380A. (NCT00653159)
Timeframe: 6 months

Intervention	percentage of randomized subjects (Number)
Paragard IUD [CuT380A]	55
Mirena IUD [LNG-IUS]	33

[back to top]

Pregnancy Rates

Proportion of subjects who became pregnant within 6 months of IUD insertion (NCT00653159)
Timeframe: 6 months

Intervention	percentage of randomized subjects (Number)
Paragard IUD [CuT380A]	9
Mirena IUD [LNG-IUS]	0

[back to top]

Retention Rate

Percentage of participants who completed the final visit (i.e., not subject to early termination or loss to follow-up) (NCT00653159)
Timeframe: 6 months

Intervention	percentage of randomized subjects (Number)
Paragard IUD [CuT380A]	55
Mirena IUD [LNG-IUS]	75

[back to top]

Device Satisfaction Rates

"Satisfaction rate is the proportion of subjects who report being happy or very happy with their assigned intrauterine contraceptive method on the date of their 6 month study visit." (NCT00653159)
Timeframe: 6 months

Intervention	percentage of subjects completing study (Number)
Paragard IUD [CuT380A]	80
Mirena IUD [LNG-IUS]	70

[back to top]

Infection

diagnosis and treatment for pelvic inflammatory disease (NCT00669396)
Timeframe: 6 months

Intervention	participants (Number)
Copper T380 IUD	0
Levonorgestrel	0

[back to top]

Use of an Effective Method of Contraception at 6 Months After Requesting Emergency Contraception

Use of a method of contraception with a typical efficacy rate >= to 92%. This includes combined hormonal contraception (combined oral contraceptive pills, the contraceptive patch and ring), sterilization, IUDs, Depo-provera, and contraceptive implants. (NCT00669396)
Timeframe: 6 months

Intervention	participants (Number)
Copper T380 IUD	9
Levonorgestrel	13

[back to top]

Pregnancy

positive urine pregnancy test at anytime within 6 months of presenting for emergency contraception. (NCT00669396)
Timeframe: 6 months

Intervention	participants (Number)
Copper T380 IUD	0
Levonorgestrel	2

[back to top]

IUD Expulsion, Removal, or Perforation

patient reports IUD expulsion, removal, or perforation OR one of these events was documented at the clinic where patient received care. (NCT00669396)
Timeframe: 6 months

Intervention	participants (Number)
Copper T380 IUD	5
Levonorgestrel	0

[back to top]

Successful Retention of IUD

(NCT00733278)
Timeframe: 6 weeks

Intervention	participants (Number)
IUD Placement	7

[back to top]

Visibility Within the Vagina of IUD Strings at All Times.

(NCT00733278)
Timeframe: At 3 days, 2 weeks and 6 weeks postpartum

Intervention	participants (Number)
IUD Strings	7

[back to top]

Insertion Rates

Insertion rates are the proportion of women in each allocation group (immediate, delayed) who ultimately had the IUD inserted within the 6 month study period. (NCT00737178)
Timeframe: By six months after medication abortion

Intervention	participants (Number)
Immediate IUD Insertion	69
Delayed IUD Insertion	65

[back to top]

Use of the IUD for Contraception at Six Months

Six months after enrollment, we determined whether or not women were using the IUD through in-person exit interviews and phone interviews. This was an intention to treat analysis, comparing the proportion of women using the IUD based on their group assignment (immediate or delayed). (NCT00737178)
Timeframe: 6 months

Intervention	participants (Number)
Immediate IUD Insertion	49
Delayed IUD Insertion	51

[back to top]

Expulsion and Removal Rates

"Expulsion rates were defined as the number of IUDs expelled from the uterus among participants who had the IUD inserted during the study.~Removal rates were defined as the number of IUDs that were electively removed by participant request among participants who had the IUD inserted during the study." (NCT00737178)
Timeframe: Within six months of medication abortion

Intervention	participants (Number)
	Expulsions	Removals
Delayed IUD Insertion	7	5
Immediate IUD Insertion	8	10

[back to top]

Tumor Uptake of 64Cu-DOTA-trastuzumab After 24 Hours

"Comparison of uptake between the HER2+ and HER2- groups, treating SUVmax measurements for individual tumors as independent observations. Statistical significance of differences in SUVmax between patient groups was assessed via a nonparametric (Wilcoxon rank-sum) test.~Radiolabel uptake for tumors was measured in terms of single-voxel maximum SUV (SUVmax; SUV = tissue activity per mL x body weight [g]/injected activity decay-corrected to time of scan)." (NCT01093612)
Timeframe: 24 hours after injection of 64 CU-DOTA-trastuzumab

Intervention	SUVmax (g/mL) (Median)
HER2+ Patients	7.0
HER2- Patients	3.7

[back to top]

Tumor Uptake of 64Cu-DOTA-trastuzumab After 48 Hours

Intervention	SUVmax (g/mL) (Median)
HER2+ Patients	8.7
HER2- Patients	4.6

[back to top]

Change in Quantities of Vaginal H2O2-producing Lactobacillus Species and Gardnerella Vaginalis

Changes in vaginal flora as assessed by qPCR quantitation of H2O2 producing Lactobacilli species and Gardnerella vaginalis. Quantitative PCR (qPCR) results are reported as log concentration of gene copies/swab specimen. (NCT01240811)
Timeframe: 2 Months

Intervention	log gene copies/swab (Median)
	Change in log Lactobacilli quantity	Change in log Garnerella vaginalis quantity
Control-No IUD	-0.6	0
Copper T380A IUD	0.1	0
Levonorgestrel IUS	-0.1	0

[back to top]

Change in Vaginal Flora

Changes in vaginal flora as assessed by Nugent score The Nugent score is calculated by microscopically assessing for the presence of large Gram-positive rods (Lactobacillus morphotypes; decrease in Lactobacillus scored as 0 to 4), small Gram-variable rods (Gardnerella vaginalis morphotypes; scored as 0 to 4), and curved Gram-variable rods (Mobiluncus spp. morphotypes; scored as 0 to 2) and can range from 0 to 10. A score of 7 to 10 is consistent with bacterial vaginosis, 4-6 is consistent with intermediate vaginal flora, and 0-3 is normal vaginal flora. (NCT01240811)
Timeframe: 2 Months

Intervention	units on a scale (Median)
Control-No IUD	0
Levonorgestrel IUS	1
Copper T380A IUD	0

[back to top]

%CD4 Expressing CCR5 HIV Co-receptor in the Cervix and Endometrium

Change in CCR5 expression on T-lymphocytes 2 months after insertion of IUD (either hormonal LNG-IUD or non-hormonal Cu-IUD) in cervix and endometrium as measured by flow cytomety (NCT01240811)
Timeframe: 2 months

Intervention	% of T-cells expressing CCR5 (Mean)
Control-No IUD	4.9
Levonorgestrel IUS	11.7
Copper T380A IUD	7.2

[back to top]

Number of Participants With Expulsion of IUD

Number of participants with Expulsion of IUDs placed at time of cesarean delivery. (NCT01439802)
Timeframe: 6 week postpartum

Intervention	Participants (Count of Participants)
	IUD Maintained	IUD Expelled
Postplacental Insertion of Intrauterine Device (IUD)	54	0

[back to top]

Number of Participants With Expulsion of IUD

Number of participants with Expulsion of IUDs placed at time of cesarean delivery. (NCT01439802)
Timeframe: 6 months postpartum

Intervention	Participants (Count of Participants)
	IUD Maintained	IUD Expelled
Postplacental Insertion of Intrauterine Device (IUD)	42	0

[back to top]

Satisfaction of IUD Placement

"Satisfaction of subjects who received an IUD at time of cesarean delivery was measured based on a telephone survey administered 6 months postpartum. A 4-point Likert scale (Very Happy/Happy, Somewhat Happy, Unsure, Unhappy) was used to evaluate participants' attitude toward the IUD." (NCT01439802)
Timeframe: 6 months postpartum

Intervention	Participants (Count of Participants)
	Very Happy/Happy	Somewhat Happy	Unsure	Unhappy
Postplacental Insertion of Intrauterine Device (IUD)	34	4	4	0

[back to top]

Number of HER2 Negative, Positive, or Equivocal Participants With Either Negative or Positive Tumor Readings

"The reading of the 64CuDOTA-trastuzumab-PET imaging of the study subjects were performed by two radiologists, one who read the first scan and the second nuclear radiologist read the remaining seven scans. To eliminate potential bias, the second nuclear radiologist was blinded to the HER2 status of the tumors as well as the location of the tumor until radiolabeled uptake was measured. XD (version 3.6; Miranda Medical) was used for image analysis.Tumor visualized as hot relative to adjacent tissue reported per radiologist as negative, positive, equivocal or unknown." (NCT01939275)
Timeframe: Up to 1 year

Intervention	participants (Number)
	HER2 Negative, Tumor Visual Negative	HER 2 Positive, Tumor Visual Negative	HER 2 Equivocal, Tumor Visual Negative	HER2 Negative, Tumor Visual Positive	HER 2 Positive, Tumor Visual Positive	HER 2 Equivocal, Tumor Visual Positive
Diagnostic (Copper Cu 64-DOTA-trastuzumab PET Scan)	5	1	2	0	0	0

[back to top]

Number of Participants With Unintended Pregnancy After Initiating the Levonorgestrel IUD Versus the Copper T380 IUD for EC at One Year.

Participants will be followed for pregnancies at regular intervals throughout the year and pregnancies will be recorded. (NCT02175030)
Timeframe: 1 year after enrollment

Intervention	Participants (Count of Participants)
Copper T380 IUD	7
LNG20 IUD	7

[back to top]

Percentage of Participants Reporting a Pregnancy

Urine pregnancy tests within 30 days after IUD insertion will be performed either at home or in clinic. We will use the total number of pregnancies per ARM and the overall number of participants analyzed per ARM to calculate, for each ARM, the percentage of participants reporting a pregnancy in the first month of use of the IUD. (NCT02175030)
Timeframe: 1 month after enrollment

Intervention	% of participants reporting pregnancy (Number)
Copper T380 IUD	0
LNG20 IUD	0.3

[back to top]

Relationship Between Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response

Relationship between patient best response to T-DM1 and measured tumor uptake of 64Cu-DOTA-trastuzumab employed a t-test with a 0.05 two-sided significance level comparing minimum uptake in responsive vs non-responsive patients. Tumor uptake measured as SUV defined as SUV = AC(tsc) Wb /[Dinj exp(-λ(tsc - tinj)] , where AC(tsc) is the activity concentration in the volume of interest (VOI, e. g., a tumor), Wb is the patient's body weight, Dinj is the activity injected at time tinj, and λ is the decay constant for the injected radioisotope. AC(tsc) is determined from the spatial density of counts acquired from the VOI. Tumor uptake was measured in terms of minimum voxel standardized uptake value, SUVmin. Response assessment adhered to Positron Emission Tomography (PET) Response Criteria in Solid Tumors (PERCIST 1.0). (NCT02226276)
Timeframe: Up to 1 year

Intervention	SUVmin (g/mL) (Median)
Diagnostic (Copper Cu 64-DOTA-trastuzumab PET)	5.1

[back to top]

Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response

Relationship between patient best response to T-DM1 and measured tumor uptake of 64Cu-DOTA-trastuzumab employed a t-test with a 0.05 two-sided significance level comparing average uptake in responsive vs non-responsive patients. Tumor uptake measured as SUV defined as SUV = AC(tsc) Wb /[Dinj exp(-λ(tsc - tinj)] , where AC(tsc) is the activity concentration in the volume of interest (VOI, e. g., a tumor), Wb is the patient's body weight, Dinj is the activity injected at time tinj, and λ is the decay constant for the injected radioisotope. AC(tsc) is determined from the spatial density of counts acquired from the VOI. Tumor uptake was measured in terms of maximum voxel standardized uptake value, SUVmax. Response assessment adhered to Positron Emission Tomography (PET) Response Criteria in Solid Tumors (PERCIST 1.0). (NCT02226276)
Timeframe: Baseline

Intervention	SUVmax (g/mL) (Median)
Diagnostic (Copper Cu 64-DOTA-trastuzumab PET)	3.1

[back to top]

Assess the Relationship of Menstrual Cycle Changes Among Women Initiating the Copper T380 IUD to Sexual Functioning and Satisfaction

# of individuals reporting that their new method had neutral or positive impact of their new contraceptive on their sex life across time points. (NCT02311478)
Timeframe: 6 months

Intervention	percentage of participants (Number)
T380A Copper IUD	80

[back to top]

Assess the Relationship of Menstrual Cycle Changes Among Women Initiating the Copper T380 IUD to Method Satisfaction and Continuation at 6 Months Post Insertion.

Determine rates of continuation and level of satisfaction with the IUD during the first 6 months of use. (NCT02311478)
Timeframe: 6-month post insertion

Intervention	percent of patients (Number)
	satisfied	continuing
T380A Copper IUD	51.6	6.4

[back to top]

Evaluate Changes in Bleeding Duration Among Women Initiating the Copper T380 IUD During the 90 Days Prior to Initiation Compared to Two 90 Periods After IUD Insertion.

Evaluate bleeding duration among women initiating the copper T380 IUD during the 90 days prior to initiation compared to two 90 periods after IUD insertion. Women will track bleeding after the insertion of the T380A IUD for 180 days. Participants will be contacted monthly to collect data. (NCT02311478)
Timeframe: 3 months prior to insertion, month 1-month 3 , month 4-month 6

Intervention	days of bleeding (Mean)
	3 months prior to insertion	month 1-month3	month 4-month 6
T380A Copper IUD	4.5	6.0	5.5

[back to top]

Concentration Levels of Secreted Cytokines and Chemokines Within the Female Genital Mucosa and Blood

The concentration levels of interleukin 1 (IL-1) family cytokines and interferon gamma-induced protein 10 (IP-10) chemokines were determined using multiplex Luminex® assays combined with a customized multi-analytical panel of 22 human cytokines and chemokines. IL-1 and IP-10 have been found to influence recruitment of HIV target cells to the female reproductive tract and this study is examining changes in IL-1 and PI-10 to gain further understanding of these mechanisms. (NCT02357368)
Timeframe: Week 1, Week 17

Intervention	pg/mL (Mean)
	IP-10 Cervicovaginal Lavage (CVL) Week 1	IP-10 CVL Week 17	IP-10 Peripheral Blood Mononuclear Cell (PBMC) Week 1	IP-10 PBMC Week 17	IL-1a CVL Week 1	IL-1a CVL Week 17	IL-1a PBMC Week 1	IL-1a PBMC Week 17	IL-1b CVL Week 1	IL-1b CVL Week 17	IL-1b PBMC Week 1	IL-1b PBMC Week 17
Depot Medroxyprogesterone Acetate (DMPA)	689.8	445.8	3298.5	3114.4	752.2	550.7	58.5	47.8	32.9	21.1	20.0	20.8
Etonogestrel Impant (Eng-Implant)	2551.1	2417.6	4107.3	3954.3	1640.2	2120.6	156.2	144.1	583.4	485.8	51.4	46.5
Levonorgestrel Intrauterine Device (Lng-IUD)	1100.2	1241.5	204.4	209.6	256.4	184.7	54.6	65.1	43.9	37.1	4.2	4.3

[back to top]

Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood

Following exposure to HIV, initial infection occurs at the genital mucosa and may involve complex interactions between a number of HIV target immune cells. HIV often uses C-C Chemokine Receptor Type 5 (CCR5) for entrance into target immune cells, causing infection of the cell. The amount of CCR5 expressing macrophages is associated with HIV infection. Cluster of differentiation 4 (CD4) T Cells are targeted and infected by HIV and CD4 percentages are used to assess immune status. CD4 counts vary by individuals and generally decrease with HIV infection. (NCT02357368)
Timeframe: Week 1, Week 17

,,,

Intervention	percentage of HIV target immune cells (Mean)
	CCR5+ CD4 T-cells Cervicovaginal Lavage (CVL) Week 1	CCR5+ CD4 T-cells CVL Week 17	CCR5+ CD4 T-cells Peripheral Blood Mononuclear Cell (PBMC) Week 1	CCR5+ CD4 T-cells PBMC Week 17	CD4% CVL Week 1	CD4% CVL Week 17	CD4% PBMC Week 1	CD4% PBMC Week 17
Depot Medroxyprogesterone Acetate (DMPA)	26.6	39.2	4.1	5.7	47.2	47.4	65.6	63.9
Etonogestrel Impant (Eng-Implant)	22.8	32.2	3.9	4.2	48.7	47.0	67.4	67.5
Levonorgestrel Intrauterine Device (Lng-IUD)	16.9	23.3	2.9	2.6	54.0	48.8	65.7	63.4
ParaGard® T 380A Intrauterine Copper Contraceptive	22.4	15.3	8.3	7.5	63.4	47.5	73.3	71.1

[back to top]

Percent of Markers of T-cell Activation and Trafficking Within the Female Genital Mucosa and Blood

T cell activation correlates with HIV infection progression and this study seeks to gain better understanding of these underlying mechanisms by assessment of HIV target cells. Changes in cluster of differentiation 38 (CD38) expression are indicators of HIV disease progression with increases seen in CD38+ when a chronic HIV infection is progressing. Human leukocyte antigen-antigen D related (HLA-DR)+ expression appears to be involved in HIV proliferation. (NCT02357368)
Timeframe: Week 1, Week 17

,,,

Intervention	percentage of T cell activation markers (Mean)
	CD38+ CD4 T-cells Cervicovaginal Lavage (CVL) Week 1	CD38+ CD4 T-cells CVL Week 17	CD38+ CD4 T-cells Peripheral Blood Mononuclear Cell (PBMC) Week 1	CD38+ CD4 T-cells PBMC Week 17	HLA-DR+ CD4 T-cells CVL Week 1	HLA-DR+ CD4 T-cells CVL Week 17	HLA-DR+ CD4 T-cells PBMC Week 1	HLA-DR+ CD4 T-cells PBMC Week 17	CD38+ Target (CCR5+ CD4+) T cells CVL Week 1	CD38+ Target (CCR5+ CD4+) T cells CVL Week 17	CD38+ Target (CCR5+ CD4+) T cells PBMC Week 1	CD38+ Target (CCR5+ CD4+) T cells PBMC Week 17	HLA-DR+ Target (CCR5+ CD4+) T cells CVL Week 1	HLA-DR+ Target (CCR5+ CD4+) T cells CVL Week 17	HLA-DR+ Target (CCR5+ CD4+) T cells PBMC Week 1	HLA-DR+ Target (CCR5+ CD4+) T cells PBMC Week 17
Depot Medroxyprogesterone Acetate (DMPA)	36.7	35.9	17.1	17.7	25.0	21.2	4.8	4.4	62.5	52.5	22.7	24.1	30.7	30.0	24.4	23.2
Etonogestrel Impant (Eng-Implant)	36.9	41.7	17.6	17.6	26.9	17.8	3.0	2.3	64.5	61.6	26.0	29.6	41.3	25.5	22.6	21.6
Levonorgestrel Intrauterine Device (Lng-IUD)	32.6	44.0	17.0	17.2	15.4	11.4	3.3	3.6	66.2	70.8	28.2	31.7	28.2	17.6	28.3	25.5
ParaGard® T 380A Intrauterine Copper Contraceptive	23.2	45.5	25.2	36.3	8.7	21.1	3.4	2.5	12.7	42.4	18.6	30.9	20.1	26.5	16.5	10.1

[back to top]

Ratio of CD4/Cluster of Differentiation 8 (CD8) T-Cells Within Female Genital Mucosa and Blood

CD4/CD8 ratios above 1 indicate a strong immune system while lower ratios indicate a viral infection. (NCT02357368)
Timeframe: Week 1, Week 17

,,,

Intervention	CD4/CD8 (Mean)
	CD4/CD8 Ratio Cervicovaginal Lavage (CVL) Week 1	CD4/CD8 Ratio CVL Week 17	CD4/CD8 Ratio Peripheral Blood Mononuclear Cell (PBMC) Week 1	CD4/CD8 Ratio PBMC Week 17
Depot Medroxyprogesterone Acetate (DMPA)	2.4	2.6	4.3	2.6
Etonogestrel Impant (Eng-Implant)	2.6	2.3	3.1	3.3
Levonorgestrel Intrauterine Device (Lng-IUD)	2.9	2.3	2.9	2.5
ParaGard® T 380A Intrauterine Copper Contraceptive	3.9	4.9	4.7	5.4

[back to top]

Number of F-18-FDG Positive Lesions That Are Detected by the Copper Cu 64 TP3805 Analog

Cu-64 results will be compared with those of F-18-FDG for: The unit of analysis will be the lesion (with potentially multiple lesions available per patient). (NCT02810873)
Timeframe: 4 hours after Cu 64 TP3805 administered

Intervention	Number of Lesions (Number)
F-18-FDG Whole-body Scan	10
No F-18-FDG Scan	14

[back to top]

SUV Measurement by 64Cu-DOTA Trastuzumab PET

"First Scan SUV Maximum, measurement by 64Cu-DOTA trastuzumab PET SUV is Standard Uptake Value. SUV = tumor activity concentration x patient body weight/injected activity decay-corrected to time of scan." (NCT02827877)
Timeframe: Baseline

Intervention	SUV (Median)
Treatment (Trastuzumab, Copper Cu 64-DOTA-trastuzumab PET)	6.6

[back to top]

Median Duration of Overall Survival

Duration of overall survival for patients that are alive (NCT03034135)
Timeframe: 14 months

Intervention	months (Median)
DSF-Cu	7.1

[back to top]

Number of Participants With Serious Adverse Events

Number of Participants with Grade 3 and 4 serious adverse events (NCT03034135)
Timeframe: 14 months

Intervention	Participants (Count of Participants)
DSF-Cu	2

[back to top]

Overall Survival

Percentage of patients that are alive (NCT03034135)
Timeframe: 6 months and 12 months

Intervention	percentage of participants (Number)
	6 months	12 months
DSF-Cu	61	35

[back to top]

Objective Response Rate

ORR will be defined as the percentage of patients with complete response (CR) or partial response (PR) according to the RANO criteria. (NCT03034135)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
	Complete response	Partial Response
DSF-Cu	0	0

[back to top]

Progression Free Survival

Percentage of patients that are free from progressive disease per RANO criteria (NCT03034135)
Timeframe: 6 months

Intervention	percentage of participants (Number)
DSF-Cu	14

[back to top]

Median Progression Free Survival

Duration of progression free survival according to RANO criteria (NCT03034135)
Timeframe: 12 months

Intervention	months (Median)
DSF-Cu	1.7

[back to top]

Number of Women With Placement of LARC

The outcome will be measured by the number of participants with LARC placement. The total number of women who expressed a desire to have postpartum contraception placed and randomized to the appropriate arm will be assessed. (NCT03305081)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
Immediate or Early Placement	10
Interval Placement	2

[back to top]

Patient Satisfaction With Method of LARC Using LARC Survey

"Number of patients satisfied with LARC obtained by LARC survey at 6-weeks, 12-weeks postpartum, and 6 months postpartum. Patients identify Yes/No response via telephone survey asking, Are you satisfied with this form of contraception?. Satisfaction determined if subject answers Yes. A single value was calculated at the end of the study by summation at all three time points." (NCT03305081)
Timeframe: 6 Weeks, 12 weeks postpartum, 6 months postpartum

Intervention	Participants (Count of Participants)
Immediate or Early Placement	10
Interval Placement	2

[back to top]

Overall Survival

Overall Survival will be assessed as a number of participants alive at 1 and 2 years. (NCT03363659)
Timeframe: 1 and 2 years

Intervention	Participants (Count of Participants)
	1 Year	2 Years
Open Label	9	2

[back to top]

6 Months Progression Free Survival (PFS)

To determine 6 month PFS of patients with unmethylated glioblastoma treated with DSF-Cu in combination with concurrent radiation and temozolomide. This was assessed by the number of participants who did not have disease progression and were alive at 6 months. (NCT03363659)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
Open Label	1

[back to top]

Substance	Relationship Strength	Studies	Classes	Roles
lactic acid Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed). 2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.	2.04	1	2-hydroxy monocarboxylic acid	algal metabolite; Daphnia magna metabolite
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	1.99	1	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
imidazole imidazole: RN given refers to parent cpd. 1H-imidazole : An imidazole tautomer which has the migrating hydrogen at position 1.	2.03	1	imidazole
phenol [no description available]	2.1	1	phenols	antiseptic drug; disinfectant; human xenobiotic metabolite; mouse metabolite
pyridine azine : An organonitrogen compound of general structure RCH=N-N=CHR or RR'C=N-N=CRR'.	2.03	1	azaarene; mancude organic heteromonocyclic parent; monocyclic heteroarene; pyridines	environmental contaminant; NMR chemical shift reference compound
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	1.96	1	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	1.99	1	pentacarboxylic acid	copper chelator
pargyline Pargyline: A monoamine oxidase inhibitor with antihypertensive properties.	2.04	1	aromatic amine
o-phthalaldehyde o-Phthalaldehyde: A reagent that forms fluorescent conjugation products with primary amines. It is used for the detection of many biogenic amines, peptides, and proteins in nanogram quantities in body fluids.. phthalaldehyde : A dialdehyde in which two formyl groups are attached to adjacent carbon centres on a benzene ring.	2.05	1	benzaldehydes; dialdehyde	epitope
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.41	1	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
sodium citrate, anhydrous Sodium Citrate: Sodium salts of citric acid that are used as buffers and food preservatives. They are used medically as anticoagulants in stored blood, and for urine alkalization in the prevention of KIDNEY STONES.. sodium citrate : The trisodium salt of citric acid.	2.01	1	organic sodium salt	anticoagulant; flavouring agent
histidine Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.	7.69	2	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.	2.6	1	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
methylmethacrylate Methylmethacrylate: The methyl ester of methacrylic acid. It polymerizes easily to form POLYMETHYL METHACRYLATE. It is used as a bone cement.. methyl methacrylate : An enoate ester having methacrylic acid as the carboxylic acid component and methanol as the alcohol component.	2.1	1	enoate ester; methyl ester	allergen; polymerisation monomer
4-xylene p-xylene : A xylene with methyl groups at positions 1 and 4.	2.1	1	xylene
propargyl bromide propargyl bromide: structure in first source	2.04	1
hematoxylin Hematoxylin: A dye obtained from the heartwood of logwood (Haematoxylon campechianum Linn., Leguminosae) used as a stain in microscopy and in the manufacture of ink.	2.21	1	organic heterotetracyclic compound; oxacycle; polyphenol; tertiary alcohol	histological dye; plant metabolite
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	1.99	1	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
dithiothreitol 1,4-dimercaptobutane-2,3-diol : A glycol that is butane-2,3-diol in which a hydrogen from each of the methyl groups is replaced by a thiol group.. 1,4-dithiothreitol : The threo-diastereomer of 1,4-dimercaptobutane-2,3-diol.	2.44	2	1,4-dimercaptobutane-2,3-diol; butanediols; dithiol; glycol; thiol	chelator; human metabolite; reducing agent
palladium Palladium: A chemical element having an atomic weight of 106.4, atomic number of 46, and the symbol Pd. It is a white, ductile metal resembling platinum, and following it in abundance and importance of applications. It is used in dentistry in the form of gold, silver, and copper alloys.. palladium : Chemical element (nickel group element atom) with atomic number 46.	2.08	1	metal allergen; nickel group element atom; platinum group metal atom
technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.	2.06	1	manganese group element atom
europium Europium: An element of the rare earth family of metals. It has the atomic symbol Eu, atomic number 63, and atomic weight 152. Europium is used in the form of its salts as coatings for cathode ray tubes and in the form of its organic derivatives as shift reagents in NMR spectroscopy.	7.03	1	f-block element atom; lanthanoid atom
cupric chloride cupric chloride: RN given refers to unlabeled parent cpd. copper(II) chloride : An inorganic chloride of copper in which the metal is in the +2 oxidation state.	2.01	1	copper molecular entity; inorganic chloride	EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor
copper sulfate Copper Sulfate: A sulfate salt of copper. It is a potent emetic and is used as an antidote for poisoning by phosphorus. It also can be used to prevent the growth of algae.. copper(II) sulfate : A metal sulfate compound having copper(2+) as the metal ion.	7.48	2	metal sulfate	emetic; fertilizer; sensitiser
pyrrolidine [no description available]	2.02	1	azacycloalkane; pyrrolidines; saturated organic heteromonocyclic parent
sodium azide Sodium Azide: A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed). sodium azide : The sodium salt of hydrogen azide (hydrazoic acid).	2.04	1	inorganic sodium salt	antibacterial agent; explosive; mitochondrial respiratory-chain inhibitor; mutagen
azides Azides: Organic or inorganic compounds that contain the -N3 group.. azide : Any nitrogen molecular entity containing the group -N3.	2.02	1	pseudohalide anion	mitochondrial respiratory-chain inhibitor
bathocuproine bathocuproine: reagent for copper; RN given refers to parent cpd	2.05	1
neocuproine neocuproine: Spectrophotometric determination of copper and ultramicro blood sugar determinations; structure; RN given refers to parent cpd. neocuproine : A member of the class of phenanthrolines that is 1,10-phenanthroline bearing two methyl substituents at positions 2 and 9.	1.96	1	phenanthrolines	chelator; copper chelator
1,7-phenanthroline [no description available]	2.68	3	phenanthroline
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	2.02	1	1,2,3-triazole
bicinchoninic acid [no description available]	6.98	1
tris(2-carboxyethyl)phosphine tris(2-carboxyethyl)phosphine: water-soluble reagent which irreversibly reduces disulfides to thiols at room temperature & is active below neutral pH; used for quantitation of iodine and iodate. TCEP : A tertiary phosphine in which phosphane is substituted with three 2-carboxyethyl groups. It is a commonly used reducing agent.	2.07	1	phosphine derivative; tricarboxylic acid	reducing agent
xylose xylopyranose: structure in first source	2.01	1	D-xylose
6-chloro-3,5-diaminopyrazine-3-carboxamide 6-chloro-3,5-diaminopyrazine-3-carboxamide: RN refers to monohydrochloride; structure given in first source	1.99	1	organochlorine compound; pyrazines
bathocuproine disulfonate bathocuproine sulfonate: reagent for copper; RN given refers to parent cpd. bathocuproine disulfonic acid : A phenanthroline that consists of 1,10-phenanthroline bearing two methyl groups at position 2 and 9 as well as two 4-sulfophenyl groups at positions 4 and 7.. copper chelator : A chelator that is any compound containing a ligand (typically organic) which is able to form a bond to a central copper atom at two or more points.	1.99	1	arenesulfonic acid; phenanthrolines	chelator
biotin vitamin B7 : Any member of a group of vitamers that belong to the chemical structural class called biotins that exhibit biological activity against vitamin B7 deficiency. Vitamin B7 deficiency is very rare in individuals who take a normal balanced diet. Foods rich in biotin are egg yolk, liver, cereals, vegetables (spinach, mushrooms) and rice. Symptoms associated with vitamin B7 deficiency include thinning hair, scaly skin rashes around eyes, nose and mouth, and brittle nails. The vitamers include biotin and its ionized and salt forms.	2.06	1	biotins; vitamin B7	coenzyme; cofactor; Escherichia coli metabolite; fundamental metabolite; human metabolite; mouse metabolite; nutraceutical; prosthetic group; Saccharomyces cerevisiae metabolite
leupeptins Leupeptins: A group of acylated oligopeptides produced by Actinomycetes that function as protease inhibitors. They have been known to inhibit to varying degrees trypsin, plasmin, KALLIKREINS, papain and the cathepsins.	1.99	1
bradykinin [no description available]	2.04	1	oligopeptide	human blood serum metabolite; vasodilator agent
acetylleucyl-leucyl-norleucinal acetylleucyl-leucyl-norleucinal: a proteasome inhibitor. acetylleucyl-leucyl-norleucinal : A tripeptide composed of N-acetylleucyl, leucyl and norleucinal residues joined in sequence.	1.99	1	aldehyde; tripeptide	cysteine protease inhibitor
enkephalin, leucine Enkephalin, Leucine: One of the endogenous pentapeptides with morphine-like activity. It differs from MET-ENKEPHALIN in the LEUCINE at position 5. Its first four amino acid sequence is identical to the tetrapeptide sequence at the N-terminal of BETA-ENDORPHIN.. Leu-enkephalin : A pentapeptide comprising L-tyrosine, glycine, glycine, L-phenylalanine and L-leucine residues joined in sequence by peptide linkages. It is an endogenous opioid peptide produced in vertebrate species, including rodents, primates and humans that results from decomposition of proenkephalin or dynorphin and exhibits antinociceptive properties.	2.04	1	pentapeptide; peptide zwitterion	analgesic; delta-opioid receptor agonist; human metabolite; mu-opioid receptor agonist; neurotransmitter; rat metabolite
sodium acetate, anhydrous Sodium Acetate: The trihydrate sodium salt of acetic acid, which is used as a source of sodium ions in solutions for dialysis and as a systemic and urinary alkalizer, diuretic, and expectorant.	2.01	1	organic sodium salt	NMR chemical shift reference compound
nadp [no description available]	1.96	1
laccase Laccase: A copper-containing oxidoreductase enzyme that catalyzes the oxidation of 4-benzenediol to 4-benzosemiquinone. It also has activity towards a variety of O-quinols and P-quinols. It primarily found in FUNGI and is involved in LIGNIN degradation, pigment biosynthesis and detoxification of lignin-derived products.	2.1	1
cystine [no description available]	1.99	1
calixarenes Calixarenes: Phenolic metacyclophanes derived from condensation of PHENOLS and ALDEHYDES. The name derives from the vase-like molecular structures. A bracketed [n] indicates the number of aromatic rings.. calixarenes : Originally macrocyclic compounds capable of assuming a basket (or "calix") shaped conformation. They are formed from p-hydrocarbyl phenols and formaldehyde. The term now applies to a variety of derivatives by substitution of the hydrocarbon cyclo{oligo[(1,3-phenylene)methylene]}.. calixarene : A macrocycle composed of 1,3-phenylene groups linked by methylene groups. The number of 1,3-phenylene units in the macrocycle is denoted by the "n" in calix[n]arene name.	2.03	1
naphthoquinones Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.	2.08	1
sphingosine sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.	2.01	1	sphing-4-enine	human metabolite; mouse metabolite
cysteine Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.	1.93	1	cysteinium	fundamental metabolite
tellurium Tellurium: An element that is a member of the chalcogen family. It has the atomic symbol Te, atomic number 52, and atomic weight 127.60. It has been used as a coloring agent and in the manufacture of electrical equipment. Exposure may cause nausea, vomiting, and CNS depression.	2.03	1	chalcogen; metalloid atom
zeolites [no description available]	2.05	1
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.33	2	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	2.17	1	benzenes; hydroxycoumarin; methyl ketone
syringaldazine syringaldazine: used for detection of laccase in sporophores of wood rotting fungi; structure	2.1	1
metallothionein Metallothionein: A low-molecular-weight (approx. 10 kD) protein occurring in the cytoplasm of kidney cortex and liver. It is rich in cysteinyl residues and contains no aromatic amino acids. Metallothionein shows high affinity for bivalent heavy metals.	2.04	1
phosphorus radioisotopes Phosphorus Radioisotopes: Unstable isotopes of phosphorus that decay or disintegrate emitting radiation. P atoms with atomic weights 28-34 except 31 are radioactive phosphorus isotopes.	2.05	1

Condition	Relationship Strength	Studies
Leucocythaemia [description not available]	2.08	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.08	1
Benign Neoplasms [description not available]	2.05	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.05	1
Glial Cell Tumors [description not available]	2.06	1
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.06	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	1.98	1
Viremia The presence of viruses in the blood.	2	1
HIV Coinfection [description not available]	2	1
Injuries, Needlestick [description not available]	2	1
HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).	2	1

chemdatabank.com

copper

Description

Cross-References

Synonyms (38)

Roles (1)

Drug Classes (2)

Pathways (28)

Research

Studies (44)

Study Types

Clinical Trials (116)

Trial Overview

Trial Outcomes

Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Length Percentile

Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Weight Percentile

Fine Motor Adaptive Development at 36 Mos of Age or at Death (Mos)

Gross Motor Development at 36 Mos of Age or at Death (Mos)

Language Development at 36 Mos of Age or at Death (Mos)

Personal-Social Development at 36 Mos of Age or at Death (Mos)

Somatic Growth Percentiles at 3 Years of Age (or at Age of Death) - Head Circumference Percentile

Breast Cancer Risk

Use of IUD

Expulsion

Percentage of Women Continuing IUD Use at 3 Months

Percentage of Women With Expulsion of an Intrauterine Device (IUD) Placed After Medical Abortion.

Expulsion Rates

Heavy Bleeding Rates

Pregnancy Rates

Retention Rate

Device Satisfaction Rates

Infection

Use of an Effective Method of Contraception at 6 Months After Requesting Emergency Contraception

Pregnancy

IUD Expulsion, Removal, or Perforation

Successful Retention of IUD

Visibility Within the Vagina of IUD Strings at All Times.

Insertion Rates

Use of the IUD for Contraception at Six Months

Expulsion and Removal Rates

Tumor Uptake of 64Cu-DOTA-trastuzumab After 24 Hours

Tumor Uptake of 64Cu-DOTA-trastuzumab After 48 Hours

Change in Quantities of Vaginal H2O2-producing Lactobacillus Species and Gardnerella Vaginalis

Change in Vaginal Flora

%CD4 Expressing CCR5 HIV Co-receptor in the Cervix and Endometrium

Number of Participants With Expulsion of IUD

Number of Participants With Expulsion of IUD

Satisfaction of IUD Placement

Number of HER2 Negative, Positive, or Equivocal Participants With Either Negative or Positive Tumor Readings

Number of Participants With Unintended Pregnancy After Initiating the Levonorgestrel IUD Versus the Copper T380 IUD for EC at One Year.

Percentage of Participants Reporting a Pregnancy

Relationship Between Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response

Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response

Assess the Relationship of Menstrual Cycle Changes Among Women Initiating the Copper T380 IUD to Sexual Functioning and Satisfaction

Assess the Relationship of Menstrual Cycle Changes Among Women Initiating the Copper T380 IUD to Method Satisfaction and Continuation at 6 Months Post Insertion.

Evaluate Changes in Bleeding Duration Among Women Initiating the Copper T380 IUD During the 90 Days Prior to Initiation Compared to Two 90 Periods After IUD Insertion.

Concentration Levels of Secreted Cytokines and Chemokines Within the Female Genital Mucosa and Blood

Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood

Percent of Markers of T-cell Activation and Trafficking Within the Female Genital Mucosa and Blood

Ratio of CD4/Cluster of Differentiation 8 (CD8) T-Cells Within Female Genital Mucosa and Blood

Number of F-18-FDG Positive Lesions That Are Detected by the Copper Cu 64 TP3805 Analog

SUV Measurement by 64Cu-DOTA Trastuzumab PET

Median Duration of Overall Survival

Number of Participants With Serious Adverse Events

Overall Survival

Objective Response Rate

Progression Free Survival

Median Progression Free Survival

Number of Women With Placement of LARC

Patient Satisfaction With Method of LARC Using LARC Survey

Overall Survival

6 Months Progression Free Survival (PFS)

Related Drugs (56)

Related Conditions (11)